Since the early 1970s, an improvement in Indigenous health promotion and services in these countries has significantly helped to reduce mortality rates, which are now approaching those of the general population 3 . Mortality rates of the Australian Indigenous population are poor when compared with these countries 3, 4 , with the mortality rate being 1.9 times that of New Zealand Maoris, and 2.4 times that of the US Indigenous population 3 . The estimated life expectancy of Indigenous Australians is comparable to certain developing countries such as Pakistan and Indonesia, although notable in Aboriginal mortality is that the majority of deaths occur in middleage, which is unlike any other country in the world 4 .
The lack of improvement in mortality has been attributed to the absence of a treaty between the Indigenous and nonIndigenous population (which has happened in the USA, New Zealand and Canada), the official Australian policy of assimilation (which discouraged the formation of specialised Indigenous programs) 3, 5 , and a lack of a single identity in many Indigenous communities, due to grouping individuals from different tribal groups in one location 6 AHWs require skills equivalent to other health professionals to meet the health needs of the communities in which they practise 16 .
Access to pharmaceuticals
The use of pharmaceuticals in Aboriginal communities has been linked to advanced disease control and prevention 17 .
Studies have been conducted showing beneficial health outcomes in patients using medications in conjunction with a model of primary health care, such as an estimated 50% reduction in natural deaths and 57% reduction in renal deaths seen in Aboriginal patients in the Northern Territory after 3 years of ACE inhibitor treatment 18 . In all the major diseases causing premature death among Indigenous people, pharmacological treatment is advised 19 .
In response to the undeniable poor health and limited access to medicines for Indigenous Australians, Section 100 of the National Health Act of 1953 (S100) was introduced in Australia in February 1999, in order to improve access to medicine for Indigenous people in designated remote areas 20 .
Under the scheme, AMS in remote areas can order bulk supplies of Pharmaceutical Benefits Scheme (PBS) medications through a selected local pharmacy, and distribute them directly, as needed, to patients 14 . Reports from participating AMS have indicated that improvements in health outcomes for Aboriginal people in areas serviced by this scheme are being achieved 21 , and the scheme has been described as one of the most significant improvements in health-service delivery for Aboriginal people in years 22 .
Dispensing pharmaceuticals at the point of consultation and the provision of primary healthcare services has been said to give a more integrated and appropriate service, minimising barriers and allowing involvement of AHWs 8 .
Although The largest proportion (29%) of the Indigenous population was located in New South Wales (NSW) 1 . It was estimated that S100 benefits 36% of the Australian Indigenous population. However, of the 153 S100-approved Aboriginal Aboriginal people from remote, regional and urban areas experienced similar barriers in their access to medicines.
Barriers remaining
There is little data exploring the current use of medication It is widely reported that many Aboriginal patients feel uncomfortable or embarrassed when accessing mainstream health services 10, 11, 13 . This presents a barrier, even if the health service, such as a doctor's surgery or pharmacy, is readily accessible to them, as in urban and regional centres.
Patients often experience high levels of anxiety and stress 11 , and even shame10 when having to consult with health authorities, which may stem not only from negative connotations and a lack of education about disease management, but also from historical influences, such as a view that accessing health services is related to dying 11, 13 .
For Aboriginal people, health is not just about the physical wellbeing of a person, but also the social, emotional and cultural wellbeing of the entire community 15 . Traditional healing remedies used by Aboriginal people for many generations contrast greatly to medicines used today.
Because of this, Aboriginal people may be unsure and untrusting about the concept of taking medication in the absence of any symptoms, such as antihypertensives and hypoglycaemic medications 26, 27 . They may also have been taught about traditional remedies to treat problems and use these in place of prescribed medicines 27 . A past study indicated that most respondents had never told a doctor that they use 'bush medicine', thinking that disclosing this is unnecessary or that bush medicine should be kept a secret among Aboriginal people 10 .
Literacy and the ability to understand instructions is another a barrier to medication regimen adherence 10, 13, 28 . Aboriginal people can have difficulty understanding when and how to take their medications, and instructions such as 'take one tablet twice a day' can be misunderstood, resulting in two tablets being taken at once, or the tablets being taken with minimal interval between 13 . A common belief among health professionals that poor compliance, or not following the doctor's 'rules', may be 'due to ignorance or laziness', can cause frustration when a patient fails to follow a management plan that would improve their health 29 . Such a belief does not take into account that the 'rules' in a consultation are culturally specific and may require knowledge that is foreign to people from a varying backgrounds 7, 30 . The use of medical terminology and complex language by health practitioners can also lead to misunderstanding, compounded by the fact that Aboriginal people may feel embarrassed or uncomfortable in asking for clarification 13 and want to end the conversation as quickly as possible. Behaviour such as looking straight ahead and saying 'yes' or 'no' may convince the educator that they have conveyed information to the patient effectively 12 . Such a communication barrier may also be caused by feelings of lack of control in the patient, differing conversational styles, lack of shared knowledge and understanding, and other cultural elements 31 .
The cost of medication is an issue for some Aboriginal patients in areas where S100 is not available. Many
Aboriginal people receive a government benefit, reducing the amount of money available for medications and health consultations 13, 14 . In many areas GPs do not offer bulkbilling and patients cannot afford the cost of a consultation 13 .
Administrative matters, such as the patient not having a current concession or pension card, or not understanding the need to carry a Medicare card, may also present barriers to GP and pharmacy services 8 . Most AMS that are not eligible for S100 divert funds from primary health services to pay for medicines or devices such as spacers 32 that are needed by their clients. This is usually in the form of an account at a local pharmacy, which may also cover the patient's copayment for their most needy clients or for children's medications. Diverting money from other programs in this way is considered necessary to assist clients obtain medications 17 .
Lack of available refrigeration 8, 27 , lack of knowledge of storage issues (for example not in sunlight or humid conditions), recurrent relocation (transient housing) and nonregular doctors and pharmacies may also play a part in an Aboriginal client's lack of adherence to the prescribed medication regemin 27 .
Access to medications may also be limited by the distance to local pharmacies and doctors' surgeries. Public transport is problematic in rural areas, and private vehicle ownership is lower among Aboriginal people 13 . However, some AMS provide transport to health-related appointments and the pharmacy for patients in need of medications 15 . In larger regional centres and urban areas Aboriginal people may live close enough to health services for travelling not to be problematic.
Further strategies for improved access to pharmaceuticals A report commissioned by the Office of Aboriginal and Torres Straight Islander Health stated that work to change the responsiveness of mainstream services should continue, but that primary health care is needed now 19 . It has been suggested that the most effective way for medicines to be supplied to Aboriginal people is through their local AMS, with assistance from community pharmacists regarding supply and support for quality use of medicines 14, 21 . It has been suggested that widening the S100 eligibility criteria to include AMS in non-remote areas would provide a benefit to a much larger proportion of the Indigenous population 14, 21 . A joint proposal from the National Aboriginal Community
Controlled Health Organisation (NACCHO), the Pharmacy Guild of Australia and the Australian Medical Association recommended that the current S100 arrangements be available to all AMS, regardless of their location 21 . The three organisations collaborated to develop a model for nonremote access. This model involved the addition of services such as the capacity for AMS to write prescriptions that could be filled at a community pharmacy without a copayment being required, and an increase in funding to address the need for quality use of medicines 21 .
What about quality use of medicines?
A question arises from the supply of medicines through S100
regarding whether quality use of medicines (QUM) is being achieved? Australian Government policy on QUM states that 'To achieve quality use of medicines, people must be provided with the most appropriate treatment, and have the knowledge and skills to use medicines to their best effect' 33 .
Because the S100 scheme does not address the interface between clients and the person supplying the pharmaceutical products, and the facilitation of dispensing has been transferred from the pharmacy to the AMS, there is limited scope in ensuring the judicious and efficacious use of medicines 21, 23 , and the provision of consumer medicines information 34 .
As a consequence, the Pharmacy Guild of Australia and NACCHO developed a pharmacist assistance program whereby pharmacists offer services such as management of AMS dispensary, education of staff including AHWs, dose administration aids, assistance with medication enquiries and the provision of medication reviews 14 . An evaluation carried out on the S100 program concluded that, although the program fostered stronger relationships between pharmacists and AHWs, it could be strengthened in terms of QUM 23 .
Patient counselling on medication use in an AMS is normally carried out by the clinic staff, not a pharmacist. To ensure safe and effective therapy it is important that the staff member have an understanding of the prescribed medication, and the required medication regimen 35 . The Pharmaceutical 
Conclusion
There is no doubt that S100 has increased the access of Indigenous Australians to medication, but QUM issues still need to be addressed. If the proposed expansion of S100 to non-remote areas proceeds, access could be improved further. However, the danger of suboptimal QUM remains until issues relating to remuneration of pharmacists are addressed, and adequate training of AHWs is achieved. Indigenous art or pamphlets on display, and staff undertaking cultural awareness training 11, 13 . However, currently such strategies have not been widely implemented.
It is unclear if this is because of perceived difficulties in implementation or achievement of goals, or simply because such strategies are not regarded as the best way to assist change.
Regarding the call for the responsiveness of mainstream services to continue while improving primary health care 'now' 19 , the described use of S100 could be regarded as a primary healthcare initiative that has been implemented within a relatively short period of time. In this instance, however, changing the responsiveness of mainstream services may take longer to achieve.
